Clinical trials: Barrett's Esophagus (BE), active
Barrett Esophagus, Barretts Esophagus With Dysplasia
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area…
- Conditions
- Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophageal Adenocarcinoma
- Trial name
- SWAT-BE (NCT05530343)
- Testing
- Seattle protocol, WATS3D brushings
- Where
- 14 sites in United States
- Volunteers
- 2,298 people
- Sponsor
- University of Colorado, Denver
Gastro Esophageal Reflux Disease, Barrett Esophagus
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
This study plans to learn more about what patients think about screening for esophageal cancer (EAC) and Barrett's esophagus (BE); a pre-cancerous condition associated with esophageal cancer.
- Trial name
- NCT06693622
- Testing
- Patient survey
- Where
- United States
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Barrett Esophagus
Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)
This is a research study to look at how a new medication compares to standard treatment for reducing acid reflux in patients with Barrett's Esophagus. The study drug is Vonoprazan.
- Trial name
- NCT07788742
- Testing
- Potassium-Competitive Acid Blockers (PCABs)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of North Carolina, Chapel Hill
Barrett Esophagus
Longitudinal Oral Microbiome Sampling for BE
This is a longitudinal cohort study to assess the impact of repeated sampling of an oral microbiome signature for Barrett's esophagus (BE).
- Trial name
- NCT05133102
- Testing
- Sample collection
- Where
- 2 sites in United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- Columbia University
Barrett's Esophagus
Enhancing Screening Practices for BE
Previous studies have shown that screening for Barrett's esophagus (BE), the main risk factor for esophageal adenocarcinoma, is under-utilized in the primary care setting.
- Trial name
- NCT07335445
- Testing
- Screening Reminder
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Rutgers, The State University of New Jersey
Barrett's Esophagus, Barrett's Esophagus With Dysplasia
Lucid BE Biomarkers Study
The goal of this study is to learn more about genetic factors that may predict if patients with Barrett's Esophagus (BE) will respond to endoscopic treatment.
- Conditions
- Barrett's Esophagus, Barrett's Esophagus With Dysplasia, Esophageal Adenocarcinoma (EAC)
- Trial name
- NCT07887568
- Testing
- Tissue
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Barrett Esophagus, Esophageal Adenocarcinoma
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or…
- Conditions
- Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
- Trial name
- ESOGUARDBE2 (NCT04295811)
- Testing
- EsoGuard (lab assay), Esophagogastroduodenoscopy
- Where
- 35 sites in United States, Netherlands
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Lucid Diagnostics, Inc.
Barrett's Esophagus, Esophageal Cancer
TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
A prospective outcomes study in patients with and esophageal cancer (EAC) and Barrett's esophagus (BE) associated neoplasia being evaluated for endoscopic eradication therapy (EET).
- Trial name
- NCT02634645
- Testing
- Endoscopic eradication therapies (EET), Esophagectomy, Chemotherapy
- Where
- 4 sites in United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Barrett's Esophagus, Intestinal Metaplasia
The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE
Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE).
- Trial name
- NCT05818072
- Testing
- One biopsy, Three biopsy, Seattle protocol
- Where
- Taiwan
- Volunteers
- 165 people
- Sponsor
- E-DA Hospital
Barrett Esophagus, Intestinal Metaplasia
Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)
A multicenter, prospective, single arm, non randomized clinical trial to evaluate the safety and efficacy of the C2 CryoBalloon Focal Ablation System (CbFAS) for the treatment of persistent dysplasia or intestinal metaplasia (IM)…
- Conditions
- Barrett Esophagus, Intestinal Metaplasia, Esophageal Dysplasia
- Trial name
- NO FEAR-BE (NCT03554356)
- Testing
- CryoBalloon Focal Ablation System
- Where
- 11 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of North Carolina, Chapel Hill
Barrett's Esophagus (BE)
Digma System First in Human (FIH) Study
Prospective, open-label, single-arm, early feasibility study (EFS) in 2 Patient cohorts: Cohort A - Dose finding / Dose response study in patients with various etiologies undergoing Esophagectomy and Cohort B - Patients with…
- Trial name
- NCT07331857
- Testing
- Endoscopic Gastrointestinal Ablation Device (EGAD)
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- Digma Medical Ltd.